China Resources Boya Bio-pharmaceutical GroupLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Xiaoming Liang
Chief executive officer
CN¥3.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 21
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings
Sep 12Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark
Jun 12China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31CEO
Xiaoming Liang (57 yo)
Mr. Xiaoming Liang serves as Non-Independent Director at Boya Bio-pharmaceutical Group Co., Ltd since February 03, 2021 and also serves as a President. He is a member of the first session of the Biotechnol...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP, CFO | 3.4yrs | CN¥1.11m | no data | |
| VP & Director | no data | CN¥93.00k | no data | |
| Vice President | 4.3yrs | CN¥1.77m | 0.014% CN¥ 1.9m | |
| Vice President | 2.8yrs | CN¥1.30m | no data | |
| President & Director | no data | CN¥2.99m | no data | |
| Vice President | 4.3yrs | CN¥2.48m | no data |
Experienced Management: 300294's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP, CFO | 3.4yrs | CN¥1.11m | no data | |
| VP & Director | less than a year | CN¥93.00k | no data | |
| President & Director | 4.3yrs | CN¥2.99m | no data | |
| Non-Employee Representative Supervisor | 8.2yrs | no data | no data | |
| Independent Director | 4.3yrs | CN¥200.00k | no data | |
| Independent Director | 4.3yrs | CN¥200.00k | no data | |
| Independent Director | 4.3yrs | CN¥200.00k | no data | |
| Chairman of the Board | 1.6yrs | no data | no data | |
| Director | 1.2yrs | no data | no data | |
| Chairman of the Supervisory Board | less than a year | no data | no data |
Experienced Board: 300294's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 20:50 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Fang Quan | China International Capital Corporation Limited |
| Bing Zhao | China Renaissance Securities |